Emerging oligonucleotide-based strategies to inhibit STAT3 signaling, such as STAT3-siRNA linked to a CpG oligonucleotide agonist of TLR9 that can target and silence STAT3 in tumor-related immune cells in the tumor microenvironment, have shown two-pronged activating effects as antitumor therapies 40, 52-54. Here, TLR9 is linked to neoplasm.